Zimmer Biomet to Acquire Paragon 28 for ~$1.2B
Shots:
- Zimmer Biomet has agreed to acquire Paragon 28 for $13.00/share in cash with an equity value of ~$1.1B & enterprise value of ~$1.2B. Closing is expected in H1’25
- As per the terms, shareholders will also get a non-tradeable CVR of $1/share on achieving revenue milestones, which is payable from $0 to $1 (calculated linearly) if Zimmer’s FY’26 net sales exceed $346M up to $361M
- The acquisition will strengthen Zimmer’s portfolio with Paragon 28’s leading platform technology along with pipeline in foot & ankle surgical solutions incl. deformity correction, joint replacement, fracture & trauma
Ref: Prnewswire | Image: Paragon 28
Related News:- Zimmer Biomet Reports the Acquisition of OrthoGrid Systems
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
